Bicara Therapeutics Inc. - BCAX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 02, 2026 | SCHEDULE 13D/A | — | 9.99% | — | View |
| Feb 17, 2026 | SCHEDULE 13G | T. Rowe Price Investment Management, Inc. | 5.9% | 3,236,595 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Vestal Point Capital, LP | 6.5% | 3,575,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ryan Wilder | 6.5% | 3,575,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 5.02% | 2,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 5.02% | 2,750,000 | View |
| Feb 12, 2026 | SCHEDULE 13G | David Kroin | 5.02% | 2,750,000 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | FMR LLC | 6.1% | 3,347,223 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 6.1% | 3,347,223 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.